Filtered By:
Condition: Atrial Fibrillation
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 2092 results found since Jan 2013.

Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation
Opinion statement Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder, which can potentially increases the risk of stroke by five-fold, thus, resulting in high public healthcare burden. Stroke prevention is vital in the management of AF patients. Vitamin K antagonists (VKA, eg, warfarin) have been the mainstay treatment to prevent ischemic stroke and systemic thromboembolism in AF patients for several decades. Despite the efficacy of warfarin, its limitations have recently driven the advent of some new antithrombotic agents, the non-VKA oral anticoagulant (NOACs, including dabigatran, ri...
Source: Current Treatment Options in Neurology - February 11, 2015 Category: Neurology Source Type: research

Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The Prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation Original Articles
Conclusions— These contemporary global data show that anticoagulant use for stroke prevention is no different in men and women with nonvalvular AF. Thromboprophylaxis was, however, suboptimal in substantial proportions of men and women, with underuse in those at moderate-to-high risk of stroke and overuse in those at low risk. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362.
Source: Circulation: Cardiovascular Quality and Outcomes - March 5, 2015 Category: Cardiology Authors: Lip, G. Y. H., Rushton-Smith, S. K., Goldhaber, S. Z., Fitzmaurice, D. A., Mantovani, L. G., Goto, S., Haas, S., Bassand, J.-P., Camm, A. J., Ambrosio, G., Jansky, P., Al Mahmeed, W., Oh, S., van Eickels, M., Raatikainen, P., Steffel, J., Oto, A., Kayani, Tags: Health policy and outcome research, Coumarins, Other anticoagulants, Arrhythmias, clinical electrophysiology, drugs Original Articles Source Type: research

Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation
Stroke is a leading cause of morbidity and mortality worldwide. Atrial fibrillation (AF) is an independent risk factor for stroke, increasing the risk five-fold. Strokes in patients with AF are more likely than other embolic strokes to be fatal or cause severe disability and are associated with higher healthcare costs, but they are also preventable. Current guidelines recommend that all patients with AF who are at risk of stroke should receive anticoagulation. However, despite this guidance, registry data indicate that anticoagulation is still widely underused. With a focus on the 2012 update of the European Society of Car...
Source: Europace - June 26, 2015 Category: Cardiology Authors: Camm, A. J., Pinto, F. J., Hankey, G. J., Andreotti, F., Hobbs, F. D. R., on behalf of the Writing Committee of the Action for Stroke Prevention alliance, on behalf of the Writing Committee of the Action for Stroke Prevention alliance, John Camm, Pinto, H Tags: REVIEW Source Type: research

Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey.
CONCLUSIONS: In this large French study, approximately 45% of thromboembolic high-risk patients were either not treated or inadequately treated. Better compliance with evidence-based guidelines is needed to reduce the burden of stroke in the AF population. PMID: 26113478 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - June 22, 2015 Category: Cardiology Authors: Sabouret P, Bricard M, Hermann MA, Cotté FE, Deret-Bixio L, Rushton-Smith S Tags: Arch Cardiovasc Dis Source Type: research

Patients with atrial fibrillation and low risk of stroke - do they really need anticoagulation?
Authors: Trusz-Gluza M, Filipecki A, Urbańczyk-Świć D Abstract Atrial fibrillation (AF) significantly increases risk of thromboembolic events, in particular the risk of stroke. Anticoagulation therapy reduces this risk and the treatment should be lifelong. However, the risk in patients with non-valvular AF is not equally distributed. There are patients at low risk. Assessment of the thromboembolic risk according to guidelines is mandatory, most frequently CHA2DS2-VASc scheme is used. In the large group with the CHA2DS2-VASc-0 (females 1) the annual risk of stroke was 0.49%, ischemic stroke 0.43%, on the other si...
Source: Polskie Archiwum Medycyny Wewnetrznej - August 28, 2015 Category: Internal Medicine Tags: Pol Arch Med Wewn Source Type: research

Abstract 203: Preventing Stroke in Patients With Atrial Fibrillation: A Review of Published Interventions to Aid Patient Decision Making Session Title: Abstract Poster Session II
Conclusion: Interventions designed to aid patient decision making around stroke prevention in AF improved a selection of patient-centered outcomes. Given the availability of multiple NOACs and an implantable device for stroke prevention in AF, there is a need to develop and evaluate new patient decision support tools.
Source: Circulation: Cardiovascular Quality and Outcomes - February 26, 2016 Category: Cardiology Authors: ONeill, E. S., Grande, S. W., Elwyn, G., Coylewright, M. Tags: Session Title: Abstract Poster Session II Source Type: research

Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials.
This article focuses on three randomised controlled trials (RCTs) that are investigating the utility of rivaroxaban, a direct, oral, factor Xa inhibitor, in additional areas of stroke prevention where data for anticoagulants are lacking: oPen-label, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment (PIONEER AF-PCI); New Approach riVaroxoban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS); and Global study comparing a rivAroxaban-based antithrombo...
Source: Thrombosis and Haemostasis - September 13, 2016 Category: Hematology Authors: Hemmrich M, Peterson ED, Thomitzek K, Weitz JI Tags: Thromb Haemost Source Type: research

Factors associated with non –vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice, up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists, and had higher socioeconomic status. Trial registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 25, 2017 Category: Cardiology Source Type: research

Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation
AbstractAtrial fibrillation (AF) is associated with significant risk of stroke and other thromboembolic events, which can be effectively prevented using oral anticoagulation (OAC) with either vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, or edoxaban. Until recently, VKAs were the only available means for OAC treatment. NOACs had similar efficacy and were safer than or as safe as warfarin with respect to reduced rates of hemorrhagic stroke or other intracranial bleeding in the respective pivotal randomized clinical trials (RCTs) of stroke prevention in non-valvular AF...
Source: Advances in Therapy - September 27, 2017 Category: Drugs & Pharmacology Source Type: research

Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.
CONCLUSION: QD NOACs prevented a significant number of strokes and caused no significant increase in MBs compared to BID NOACs which leads to significant net cost savings for NVAF patients in the US. PMID: 30265159 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - September 29, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research

Stroke Severity in Patients on Non-Vitamin K Antagonist Oral Anticoagulants with a Standard or Insufficient Dose.
CONCLUSION:  Use of warfarin with a therapeutic intensity or standard-dosed NOACs was associated with a relatively mild stroke in the patients with NVAF. PMID: 30453351 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 19, 2018 Category: Hematology Authors: Jung YH, Choi HY, Lee KY, Cheon K, Han SW, Park JH, Cho HJ, Park HJ, Nam HS, Heo JH, Lee HS, Kim YD Tags: Thromb Haemost Source Type: research

Residual Stroke Risk in Patients with Atrial Fibrillation Treated with Non-Vitamin K Oral Anticoagulants: An 8-Year Retrospective Cohort Study
Conclusions: Stroke developed in NVAF patients despite being on NOACs, with the majority being female, older, and hypertensive. Surprisingly, in general they had reasonable lipid and diabetic control.Cerebrovasc Dis Extra 2021;11:9 –14
Source: Cerebrovascular Diseases Extra - January 18, 2021 Category: Neurology Source Type: research

Anticoagulants for stroke prevention in heart failure with reduced ejection fraction
AbstractImpaired left-ventricular ejection-fraction (LV-EF) is a known risk factor for ischemic stroke and systemic embolism in patients with heart failure (HF) even in the absence of atrial fibrillation. While stroke risk is inversely correlated with LV-EF in HF patients with sinus rhythm, strategies using anticoagulation with Vitamin-K antagonists (VKA) were futile as the increase in major bleedings outweighed the potential benefit in stroke reduction. Non-Vitamin K oral anticoagulants (NOACs) proved to be an effective and in general safer approach for stroke prevention in patients with atrial fibrillation and may also h...
Source: Clinical Research in Cardiology - August 27, 2021 Category: Cardiology Source Type: research

Stroke and Systemic Thromboembolism according to CHA < sub > 2 < /sub > DS < sub > 2 < /sub > -VASc Score in Contemporary Korean Patients with Atrial Fibrillation
CONCLUSION: Contemporary AF patients have a stroke rate about one-fifth that in OAC-naïve AF patients and exhibit different stroke risk factors.STUDY REGISTRATION: ClinicalTrials.gov (NCT02786095).PMID:35352882 | DOI:10.3349/ymj.2022.63.4.317
Source: Yonsei Medical Journal - March 30, 2022 Category: Universities & Medical Training Authors: Kyung Bae Lee Tae-Hoon Kim Junbeom Park Jin-Kyu Park Ki-Woon Kang Jun Kim Hyung Wook Park Eue-Keun Choi Jin-Bae Kim Young Soo Lee Jaemin Shim Boyoung Joung Source Type: research